Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
Tesla Keeps Graphite Supply Deal with Syrah Resources After Progress on Quality Issues 
Sable Offshore Wins Key Court Battle Over California Oil Pipeline 
Morgan Stanley Upgrades Winbond and Nanya to Overweight on Strong Memory Chip Market Outlook 
Anthropic Files for IPO, Signaling a New Era for Public AI Investments in 2026 
DBS Expands Wealth Centre Network Across Asia in Largest Physical Growth Push Yet 
Ryan Kavanaugh and Acme AI & FX Bets on Artificial Intelligence to Reinvent Film Production Economics 
Trump Adviser’s Investment in Thrive Capital Draws Scrutiny Over Federal Contracts 
SoftBank to Invest €75 Billion in France AI Data Center Expansion by 2031 
US Quantum Stocks Surge After $2 Billion Government Investment 
UAW Calls Strike at Michigan Axle Plant Supplying GM Pickup Trucks 
Alphabet Unveils $80 Billion Capital Raise to Accelerate AI Expansion, Secures $10 Billion Backing from Berkshire Hathaway 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
Universal Music Group Rejects Pershing Square Takeover Proposal 
Fonterra to End Fitch Ratings Coverage as Agency Plans Withdrawal 
PLANO, Texas, April 11, 2016 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Financial Officer, are scheduled to present at the 15th Annual Needham Healthcare Conference in New York, NY.
| Event: | 15th Annual Needham Healthcare Conference |
| Date: | Wednesday, April 13, 2016 |
| Time: | 9:20 am ET |
A webcast of the Company’s presentation will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the presentation will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Financial Officer (972) 668-4106 [email protected] Jennifer Armstrong, Media Relations (214) 618-4823 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
